Search filters
Filters
Clear All

Phase

  • 13
  • 1
  • 10
  • 6
  • 175
  • 206
  • 166
  • 1
  • 5
  • 200

Found 206 cc-cancer-center trials

A listing of cc-cancer-center medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

UPCC 28822: A Phase 2 Study of Neoadjuvant PARP Inhibition followed by Radical Prostatectomy in Patients with Unfavorable Intermediate-Risk or High-Risk Prostate Cancer with BRCA1/2 Gene Alterations (NePtune)

99 years and younger
All genders
Phase 2 open-label, single-arm clinical trial evaluating the efficacy and safety of neoadjuvant olaparib + LHRH agonist administered for 6 months prior to radical prostatectomy (RP) in men with unfavorable intermediate-risk or high-risk localized prostate cancer. All patients must have confirmed germline or somatic BRCA1/2 gene mutation. We would like …
Learn More

UPCC 45423 A Phase 1, Dose Escalation, and Cohort Expansion Study Evaluating NX-5948, a Brutons Tyrosine Kinase (BTK) Degrader, in Adults with Relapsed/Refractory B-cell Malignancies

99 years and younger
All genders
This is a first-in-human Phase 1a/1b multicenter, open-label study designed to evaluate the safety and anti-cancer activity of NX-5948 in patients with advanced B-cell malignancies. We would like to rely on WCG IRB as the IRB of record for this study.
Learn More

UPCC 40423 A Phase II Study of Reduced Dose Post Transplantation Cyclophosphamide as GvHD Prophylaxis in Adult Patients with Hematologic Malignancies Receiving HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation

99 years and younger
All genders
The goal of this clinical trial is to determine the effectiveness of Reduced Dose Post-Transplant Cyclophosphamide (PTCy) in patients with hematologic malignancies after receiving an HLA-Mismatched Unrelated Donor (MMUD). We would like to rely on NMDP IRB as the IRB of record for this study.
Learn More

UPCC 32423 An Open-label, Multicenter Phase 2 Study Evaluating the Efficacy and Safety of CRG-022, A CD22-Directed Autologous Chimeric Antigen Receptor (CAR) T-cell Therapy in Participants With Relapsed/Refractory Large B-Cell Lymphoma After CD19-Direc

99 years and younger
All genders
This is a prospective, open-label, multi-center clinical study designed to evaluate the safety, tolerability, efficacy, pharmacokinetics, pharmacodynamics, and immunogenicity of CRG-022, a CD22-directed Autologous Chimeric Antigen Receptor (CAR) T-cell Therapy for the treatment of relapsed or refractory large B-cell lymphoma.
Learn More

UPCC 47423:A Multicentre, Phase II, Randomised, Open-label Study to Evaluate the Efficacy of Acalabrutinib in Combination with Venetoclax and Rituximab in Participants with Treatment Naïve Mantle Cell Lymphoma (TrAVeRse)

99 years and younger
All genders
TrAVeRse is a multicenter, open-label, randomized, Phase II study of AVR in treatment naive MCL participants. The primary objective is to assess the rate of MRD-negative CR at end of induction after completing 13 cycles of AVR. Participants achieving an MRD-negative CR at end of AVR induction will be randomized …
Learn More

UPCC 09818: An Open-Label, Randomized Phase 3 Study to Evaluate Enfortumab Vedotin vs. Chemotherapy in Subjects with Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)

99 years and younger
All genders
The main purpose of this study is to collect information to determine if a medicine called enfortumab vedotin (EV) is effective, safe and comparable to the docetaxel or paclitaxel for cancer of the urinary system (urothelial cancer, including cancer of the bladder, renal pelvis, ureter or urethra) that has spread …
Learn More

UPCC 12023: Autologous Chimeric Antigen Receptor Engineered T Cell Immunotherapy for Desensitization in Patients Awaiting Kidney Transplantation

99 years and younger
All genders
Please refer to Protocol Section 2 (Study Hypothesis/Objectives). Please refer to Protocol Section 3.5 (Primary Endpoints). Please refer to Protocol Section 3.6 (Secondary Endpoints).
Learn More

UPCC 18122: A Phase III, Randomized, Open-Label, Multicenter Study Evaluating The Efficacy And Safety of Giredestrant Plus Everolimus Compared With Exemestane Plus Everolimus In Patients With Estrogen Receptor-Positive, Her2-Negative, Locally Advanced

99 years and younger
All genders
This study will evaluate the efficacy and safety of giredestrant plus everolimus compared with exemestane plus everolimus in participants with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer who have had previous treatment with CDK4/6is and endocrine therapy, either in the locally …
Learn More

UPCC 37922:A Phase 1 Open-Label, Multi-Center, Safety and Efficacy Study of PRT3645 in Participants with Select Advanced or Metastatic Solid Tumors

99 years and younger
All genders
Please refer to Protocol PRT3645-01, Section 5 (Objectives, Endpoints, and Estimands) Please refer to Protocol PRT3645-01, Section 5 (Objectives, Endpoints, and Estimands) Please refer to Protocol PRT3645-01, Section 5 (Objectives, Endpoints, and Estimands)
Learn More

UPCC 02423: Phase 2 study of cevostamab consolidation following BCMA CAR T cell therapy for relapsed/refractory multiple myeloma

99 years and younger
All genders
Please refer to the protocol, Section 2 (Objectives and Endpoints) Please refer to the protocol, Section 2 (Objectives and Endpoints) Please refer to the protocol, Section 2 (Objectives and Endpoints)
Learn More
101 - 110 of 206